These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1142 related items for PubMed ID: 25385550

  • 1. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
    Schmidt T, Paust HJ, Krebs CF, Turner JE, Kaffke A, Bennstein SB, Koyro T, Peters A, Velden J, Hünemörder S, Haag F, Steinmetz OM, Mittrücker HW, Stahl RA, Panzer U.
    Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
    [Abstract] [Full Text] [Related]

  • 2. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

  • 3. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 01; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 4. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K, Kalies K, Szyska M, Humrich JY, Amann K, Manz RA.
    Arthritis Rheum; 2012 Apr 01; 64(4):1237-46. PubMed ID: 22006377
    [Abstract] [Full Text] [Related]

  • 5. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L, Chen HP, Ma Q.
    Immunol Lett; 2014 Sep 01; 161(1):76-80. PubMed ID: 24837470
    [Abstract] [Full Text] [Related]

  • 6. IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A, Tesch G, Kinoshita K, Maron R, Weiner HL, Kelley VR.
    J Immunol; 1999 Dec 15; 163(12):6884-91. PubMed ID: 10586090
    [Abstract] [Full Text] [Related]

  • 7. Ets Family Transcription Factor Fli-1 Promotes Leukocyte Recruitment and Production of IL-17A in the MRL/Lpr Mouse Model of Lupus Nephritis.
    Sato S, Zhang XK, Temmoku J, Fujita Y, Matsuoka N, Yashiro-Furuya M, Asano T, Kobayashi H, Watanabe H, Migita K.
    Cells; 2020 Mar 14; 9(3):. PubMed ID: 32183259
    [Abstract] [Full Text] [Related]

  • 8. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice.
    Monneaux F, Dumortier H, Steiner G, Briand JP, Muller S.
    Int Immunol; 2001 Sep 14; 13(9):1155-63. PubMed ID: 11526096
    [Abstract] [Full Text] [Related]

  • 9. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E, Lenda DM, Kelley VR.
    J Immunol; 2003 Apr 01; 170(7):3915-25. PubMed ID: 12646661
    [Abstract] [Full Text] [Related]

  • 10. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
    Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A.
    Arthritis Rheum; 2002 Nov 01; 46(11):3083-95. PubMed ID: 12428253
    [Abstract] [Full Text] [Related]

  • 11. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.
    Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, Zhu FH, Yang YF, Li Y, Tang W, Zuo JP.
    Arthritis Rheum; 2011 Aug 01; 63(8):2445-55. PubMed ID: 21484768
    [Abstract] [Full Text] [Related]

  • 12. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec 01; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

  • 13. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice.
    Fujii T, Okada M, Fujita Y, Sato T, Tanaka M, Usui T, Umehara H, Mimori T.
    J Autoimmun; 2009 Sep 01; 33(2):125-34. PubMed ID: 19596182
    [Abstract] [Full Text] [Related]

  • 14. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
    Goury A, Meghraoui-Kheddar A, Belmokhtar K, Vuiblet V, Ortillon J, Jaisson S, Devy J, Le Naour R, Tabary T, Cohen JH, Schmidt AM, Rieu P, Touré F.
    J Immunol; 2015 Apr 15; 194(8):3612-22. PubMed ID: 25762779
    [Abstract] [Full Text] [Related]

  • 15. CD4(+)B220(+)TCRγδ(+) T cells produce IL-17 in lupus-prone MRL/lpr mice.
    Qiu F, Li T, Zhang K, Wan J, Qi X.
    Int Immunopharmacol; 2016 Sep 15; 38():31-9. PubMed ID: 27235595
    [Abstract] [Full Text] [Related]

  • 16. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
    Merino R, Iwamoto M, Fossati L, Izui S.
    J Immunol; 1993 Dec 01; 151(11):6509-16. PubMed ID: 7902378
    [Abstract] [Full Text] [Related]

  • 17. T cell-derived IFN-γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus.
    Düster M, Becker M, Gnirck AC, Wunderlich M, Panzer U, Turner JE.
    Eur J Immunol; 2018 Aug 01; 48(8):1364-1375. PubMed ID: 29671873
    [Abstract] [Full Text] [Related]

  • 18. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.
    J Am Soc Nephrol; 2005 Dec 01; 16(12):3592-601. PubMed ID: 16267157
    [Abstract] [Full Text] [Related]

  • 19. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A, Hall SR, Körner M, Herrmann M, Schmid RA, Frese S.
    Arthritis Res Ther; 2016 Oct 22; 18(1):243. PubMed ID: 27770825
    [Abstract] [Full Text] [Related]

  • 20. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
    Chuan W, Wu-qing W, Zhu-wen Y, Zuo L.
    Lupus; 2014 Sep 22; 23(10):994-1005. PubMed ID: 24756437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.